#South Korea #Seoul #Ottimo Pharma #LOTTE BIOLOGICS #antibody therapeutics

LOTTE BIOLOGICS and Ottimo Pharma: A New Era in Antibody Manufacturing

On June 19, 2025, LOTTE BIOLOGICS proudly announced its latest venture into global biopharmaceutical collaborations with the signing of a contract manufacturing agreement with Ottimo Pharma. This deal is pivotal as it focuses on the production of cutting-edge antibody therapeutics, specifically Jankistomig, a first-of-its-kind PD1/VEGFR2 dual pathway antibody designed to improve the lives of cancer patients.

The official signing ceremony took place at LOTTE BIOLOGICS’ booth within the Boston Convention and Exhibition Center during the BIO INTERNATIONAL 2025 event, further emphasizing the significance of this agreement in the biopharmaceutical sector. The Syracuse Bio Campus in New York will be the production site for these therapeutics, showcasing LOTTE BIOLOGICS' commitment to state-of-the-art biomanufacturing processes.

James Park, CEO of LOTTE BIOLOGICS, expressed great optimism regarding this partnership. He stated, "This agreement serves as further validation of our competitiveness as a CDMO in the global antibody therapeutics market. We will continue striving... to become a company that delivers greater value to both our partners and patients." This sentiment echoes the company's ambition to be at the forefront of biopharmaceutical innovation while maintaining high manufacturing standards.

In alignment with this, Joseph Shultz, Vice President of Technical Development and Manufacturing at Ottimo Pharma, emphasized the importance of this collaboration. He mentioned that partnering with LOTTE BIOLOGICS enhances Ottimo’s operational readiness, supporting their rapid path to Investigational New Drug (IND) submission and clinical trial initiation. Such collaborations are vital in the fast-paced environment of drug development, where time and precision are critical to bringing effective therapies to market.

Expanding Capabilities in Biopharmaceuticals

LOTTE BIOLOGICS is not only focused on immediate goals but is also planning for future growth. Currently, operations at the Syracuse Bio Campus involve a comprehensive range of Contract Development and Manufacturing Organization (CDMO) services. The facility has a total production capacity of 40,000 liters, backed by eight 5,000-liter stainless steel bioreactors, well-equipped laboratories, and widespread regulatory approvals.

Looking ahead, the company has ambitious plans with the development of its Plant 1 at the Songdo Bio Campus, set to open in 2027. This facility will feature a significant manufacturing capacity of 120,000 liters, allowing LOTTE BIOLOGICS to handle extensive global contracts. The company's strategic expansion initiatives aim to position them prominently in the antibody therapeutics and Antibody-Drug Conjugates (ADC) market, broadening the scope of treatments available to patients worldwide.

Strategic Collaborations in Global Markets

Recently, LOTTE BIOLOGICS has been actively expanding its network of partnerships with various global biotechnology firms across both Asia and Europe. These collaborations play an essential role in honing the company's strengths in biomanufacturing and establishing a foothold in the competitive CDMO market.

In addition to entering agreements like the one with Ottimo Pharma, LOTTE BIOLOGICS is enhancing its service offerings through strategic collaborations with global Contract Development Organizations (CDOs) and Drug Product (DP) companies. This integrated approach aims to provide clients with tailored solutions ranging from early drug development stages to commercialization, catering to the diverse needs of modern biopharmaceutical companies.

Commitment to Quality and Innovation

LOTTE BIOLOGICS is dedicated to delivering high-quality medicines in accordance with international standards, ensuring safety and efficacy for patients. By investing in advanced technologies and maintaining a focus on comprehensive development, LOTTE BIOLOGICS reinforces its mission to offer innovative therapies that contribute to a healthier world. As they look forward to their plans for additional manufacturing facilities, the company is poised to continue shaping the future of antibody therapeutics on a global scale.

For more information about LOTTE BIOLOGICS and their services, you can visit www.lottebiologics.com.